337 related articles for article (PubMed ID: 18954937)
1. Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients.
Sloand EM; Pfannes L; Scheinberg P; More K; Wu CO; Horne M; Young NS
Exp Hematol; 2008 Dec; 36(12):1616-24. PubMed ID: 18954937
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic significance of measurement of the receptor for urokinase-type plasminogen activator on granulocytes and in plasma from patients with paroxysmal nocturnal hemoglobinuria.
Gao W; Wang Z; Bai X; Li Y; Ruan C
Int J Hematol; 2002 May; 75(4):434-9. PubMed ID: 12041678
[TBL] [Abstract][Full Text] [Related]
3. The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria.
Ploug M; Plesner T; Rønne E; Ellis V; Høyer-Hansen G; Hansen NE; Danø K
Blood; 1992 Mar; 79(6):1447-55. PubMed ID: 1312369
[TBL] [Abstract][Full Text] [Related]
4. Excess soluble urokinase-type plasminogen activator receptor in the plasma of patients with paroxysmal nocturnal hemoglobinuria inhibits cell-associated fibrinolytic activity.
Ninomiya H; Hasegawa Y; Nagasawa T; Abe T
Int J Hematol; 1997 Apr; 65(3):285-91. PubMed ID: 9114600
[TBL] [Abstract][Full Text] [Related]
5. [Diagnostic significance of measurement of the receptor for urokinase-type plasminogen activator on granulocytes and in plasma from patients with paroxysmal nocturnal hemoglobinuria].
Gao W; Wang Z; Zhou Y
Zhonghua Nei Ke Za Zhi; 2001 Nov; 40(11):740-3. PubMed ID: 11930678
[TBL] [Abstract][Full Text] [Related]
6. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Plesner T; Behrendt N; Ploug M
Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
[TBL] [Abstract][Full Text] [Related]
7. A soluble form of the urokinase plasminogen activator receptor (suPAR) can bind to hematopoietic cells.
Mizukami IF; Todd RF
J Leukoc Biol; 1998 Aug; 64(2):203-13. PubMed ID: 9715260
[TBL] [Abstract][Full Text] [Related]
8. A soluble form of the glycolipid-anchored receptor for urokinase-type plasminogen activator is secreted from peripheral blood leukocytes from patients with paroxysmal nocturnal hemoglobinuria.
Ploug M; Eriksen J; Plesner T; Hansen NE; Danø K
Eur J Biochem; 1992 Sep; 208(2):397-404. PubMed ID: 1325906
[TBL] [Abstract][Full Text] [Related]
9. The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria.
Rønne E; Pappot H; Grøndahl-Hansen J; Høyer-Hansen G; Plesner T; Hansen NE; Danø K
Br J Haematol; 1995 Mar; 89(3):576-81. PubMed ID: 7734357
[TBL] [Abstract][Full Text] [Related]
10. Paroxysmal nocturnal hemoglobinuria: current issues in pathophysiology and treatment.
Young NS
Curr Hematol Rep; 2005 Mar; 4(2):103-9. PubMed ID: 15720958
[TBL] [Abstract][Full Text] [Related]
11. The PIG-A mutation and absence of glycosylphosphatidylinositol-linked proteins do not confer resistance to apoptosis in paroxysmal nocturnal hemoglobinuria.
Ware RE; Nishimura J; Moody MA; Smith C; Rosse WF; Howard TA
Blood; 1998 Oct; 92(7):2541-50. PubMed ID: 9746796
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the expression of glycosylphosphatidylinositol anchored proteins on platelets from patients with paroxysmal nocturnal hemoglobinuria.
Maciejewski JP; Young NS; Yu M; Anderson SM; Sloand EM
Thromb Res; 1996 Sep; 83(6):433-47. PubMed ID: 8885138
[TBL] [Abstract][Full Text] [Related]
13. Paroxysmal nocturnal hemoglobinuria: the price for a chance.
Bessler M
Schweiz Med Wochenschr; 1996 Nov; 126(45):1912-21. PubMed ID: 8946596
[TBL] [Abstract][Full Text] [Related]
14. The molecular basis of paroxysmal nocturnal hemoglobinuria.
Rosti V
Haematologica; 2000 Jan; 85(1):82-7. PubMed ID: 10629597
[TBL] [Abstract][Full Text] [Related]
15. Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor.
Høyer-Hansen G; Pessara U; Holm A; Pass J; Weidle U; Danø K; Behrendt N
Biochem J; 2001 Sep; 358(Pt 3):673-9. PubMed ID: 11535128
[TBL] [Abstract][Full Text] [Related]
16. Glycosylphosphatidylinositol-anchor-deficient mice: implications for clonal dominance of mutant cells in paroxysmal nocturnal hemoglobinuria.
Kawagoe K; Kitamura D; Okabe M; Taniuchi I; Ikawa M; Watanabe T; Kinoshita T; Takeda J
Blood; 1996 May; 87(9):3600-6. PubMed ID: 8611683
[TBL] [Abstract][Full Text] [Related]
17. Crystallization of soluble urokinase receptor (suPAR) in complex with urokinase amino-terminal fragment (1-143).
Huang M; Mazar AP; Parry G; Higazi AA; Kuo A; Cines DB
Acta Crystallogr D Biol Crystallogr; 2005 Jun; 61(Pt 6):697-700. PubMed ID: 15930623
[TBL] [Abstract][Full Text] [Related]
18. Molecular basis of paroxysmal nocturnal hemoglobinuria.
Parker CJ
Stem Cells; 1996 Jul; 14(4):396-411. PubMed ID: 8843541
[TBL] [Abstract][Full Text] [Related]
19. Paroxysmal nocturnal hemoglobinuria: stem cells and clonality.
Brodsky RA
Hematology Am Soc Hematol Educ Program; 2008; ():111-5. PubMed ID: 19074067
[TBL] [Abstract][Full Text] [Related]
20. Clinical roundtable monograph: Paroxysmal nocturnal hemoglobinuria: a case-based discussion.
Szer J; Hill A; Weitz IC
Clin Adv Hematol Oncol; 2012 Nov; 10(11 Suppl 21):1-16. PubMed ID: 23271156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
